BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, Pae CU. The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study. Clin Psychopharmacol Neurosci 2019;17:495-502. [PMID: 31671486 DOI: 10.9758/cpn.2019.17.4.495] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Lee KH, Bahk WM, Lee SJ, Serretti A, Pae CU. A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat. Clin Psychopharmacol Neurosci 2021;19:160-5. [PMID: 33508800 DOI: 10.9758/cpn.2021.19.1.160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Seo JS, Bahk WM, Woo YS, Park YM, Kim W, Jeong JH, Shim SH, Lee JG, Jang SH, Yang CM, Wang SM, Jung MH, Sung HM, Choo IH, Yoon BH, Lee SY, Jon DI, Min KJ. Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary. Clin Psychopharmacol Neurosci 2021;19:751-72. [PMID: 34690130 DOI: 10.9758/cpn.2021.19.4.751] [Reference Citation Analysis]
3 Lee KH, Bahk WM, Lee SJ, Pae CU. Effectiveness and Tolerability of Korean Red Ginseng Augmentation in Major Depressive Disorder Patients with Difficult-to-treat in Routine Practice. Clin Psychopharmacol Neurosci 2020;18:621-6. [PMID: 33124595 DOI: 10.9758/cpn.2020.18.4.621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Lee KH, Park GY, Bahk WM, Lee SJ, Pae CU. The Usefulness and Clinical Characteristics of Antidepressant Use for Stroke Patients with Rehabilitation Program: An Exploratory Analysis. Clin Psychopharmacol Neurosci 2020;18:445-9. [PMID: 32702223 DOI: 10.9758/cpn.2020.18.3.445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Caldiroli A, Capuzzi E, Tagliabue I, Capellazzi M, Marcatili M, Mucci F, Colmegna F, Clerici M, Buoli M, Dakanalis A. Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review. Int J Mol Sci 2021;22:13070. [PMID: 34884874 DOI: 10.3390/ijms222313070] [Reference Citation Analysis]
6 Kotzalidis GD, Rapinesi C, Chetoni C, De Filippis S. Aripiprazole IM depot as an option for the treatment of bipolar disorder. Expert Opin Pharmacother 2021;22:1407-16. [PMID: 33847183 DOI: 10.1080/14656566.2021.1910236] [Reference Citation Analysis]
7 Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS. Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clin Psychopharmacol Neurosci 2020;18:153-8. [PMID: 31958916 DOI: 10.9758/cpn.2020.18.1.153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]